MannKind Corporation develops treatments for serious medical conditions, focusing on diabetes and cardiometabolic diseases. Its primary product is Afrezza®, an ultra rapid-acting inhaled insulin that utilizes Technosphere® technology. The company also offers Furoscix ReadyFlow™, which allows patients to manage fluid buildup at home. MannKind operates in the biopharmaceutical sector, targeting patients with diabetes and orphan lung diseases.
